Resolvyx Pharmaceuticals
Resolvyx Pharmaceuticals develops therapeutics with small molecule lipid mediators for the treatment of inflammatory diseases
About Resolvyx Pharmaceuticals
Resolvyx Pharmaceuticals focuses on developing innovative therapies that target inflammation and immune responses to treat chronic diseases. The company operates in the biopharmaceutical sector, aiming to address unmet medical needs in conditions such as asthma, cardiovascular diseases, and neurodegenerative disorders. Resolvyx's business model revolves around research and development, leveraging proprietary technology to create novel drug candidates. Revenue is generated through partnerships, licensing agreements, and potential future product sales. The primary clients include healthcare providers, pharmaceutical companies, and research institutions. The market is highly competitive, with a strong emphasis on scientific innovation and regulatory compliance.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VC✓Equity / VC | Nov 2010 | $2.5M | $125M | Undisclosed | — |
| DEBT✓Debt | Jun 2010 | $1.2M | — | Undisclosed | — |
Growth signals
Latest recorded traffic for Resolvyx Pharmaceuticals is 210 monthly website visits. Resolvyx Pharmaceuticals's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Resolvyx Pharmaceuticals in the Cambridge ecosystem
The Resolvyx Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A7 investors entered at this stage
Atlas Venture
CHL Medical Partners
Flagship Pioneering- QLQVT Financial LP
Biogen
Flagship Ventures
Radius Ventures
Other known investors2 additional known investors
Brigham and Women's Hospital
Harvard Medical School
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Resolvyx Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Resolvyx Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









